Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

BACKGROUND: Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the insulin-like growth factor 1 receptor (IGF1R), re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xing-Ming, Zhu, Hua-Yu, Bai, Wen-Dong, Wang, Ting, Wang, Lei, Chen, Ying, Yang, An-Gang, Jia, Lin-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974046/
https://www.ncbi.nlm.nih.gov/pubmed/24571711
http://dx.doi.org/10.1186/1471-2407-14-134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974046/
https://www.ncbi.nlm.nih.gov/pubmed/24571711
http://dx.doi.org/10.1186/1471-2407-14-134

Ejemplares similares